Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002028 · ClinicalTrials.gov registry record · NA

A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)

A NA study of HIV Infections, sponsored by Bristol-Myers Squibb.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002028: Completed NA study of HIV Infections, sponsored by Bristol-Myers Squibb.

NCT00002028 is a NA study of HIV Infections that has completed, run by Bristol-Myers Squibb. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002028, a NA study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program due to protocol exclusion or geographic location.

Conditions Studied

HIV Infections

Interventions

  • DRUG Didanosine

Study Locations (1)

New Jersey

  • Bristol - Myers Squibb Co - Princeton

Trial Details

FieldValue
Phase NA
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00002028 record still lists

NCT00002028 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Didanosine is the first listed.

NCT00002028 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002028 about?

NCT00002028 is a clinical study titled "A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)". The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program due to protocol exclusion or geo...

What is the current status of trial NCT00002028?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002028 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002028?

The interventions under investigation include: Didanosine (DRUG).

Who is sponsoring clinical trial NCT00002028?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002028 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002028, the US trial registry maintained by the National Library of Medicine. NCT00002028 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.